Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
OS Therapies Incorporated (OSTX)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/21/2025: OSTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -39.53% | Avg. Invested days 15 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 74.14M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 828397 | Beta - | 52 Weeks Range 1.58 - 7.00 | Updated Date 11/16/2024 |
52 Weeks Range 1.58 - 7.00 | Updated Date 11/16/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.32 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 90743547 | Price to Sales(TTM) - |
Enterprise Value 90743547 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 20884600 | Shares Floating 16528053 |
Shares Outstanding 20884600 | Shares Floating 16528053 | ||
Percent Insiders 24.84 | Percent Institutions - |
AI Summary
OS Therapies Incorporated: A Comprehensive Overview
Company Profile
History and Background:
OS Therapies Incorporated (NASDAQ: OSTX) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in San Diego, California. They focus on developing novel therapies for musculoskeletal and ophthalmic conditions. Their lead product, STRIDE, is a biologic treatment for osteoarthritis of the knee.
Core Business Areas:
- Musculoskeletal: Degenerative joint diseases like osteoarthritis.
- Ophthalmic: Conditions affecting the eye, particularly diabetic macular edema.
Leadership and Structure:
- Dr. Michael K. McCune: President & CEO
- Dr. Brian M. Staszewski: Chief Development Officer
- Mr. Brian Lunghi: Chief Financial Officer
- Board of Directors: Dr. Michael K. McCune, Dr. Michael L. Evans, Dr. Steven G. Roth, Mr. Charles P. Geyer, and Ms. Heather K. Carpenter.
Top Products and Market Share:
- STRIDE: A recombinant human protein targeting knee osteoarthritis. Currently in Phase III clinical trials.
- OST-PC01: A T-cell therapy for the treatment of diabetic macular edema. In Phase II clinical trials.
Market Share:
- STRIDE: Targeting a market estimated at $12 billion in the US alone.
- OST-PC01: Targeting a market estimated at over $1 billion.
Market Performance:
- STRIDE: Demonstrated significant pain reduction and improved function in Phase IIa trials.
- OST-PC01: Initial data suggests improvement in vision with favorable safety profile.
Total Addressable Market:
OS Therapies Incorporated operates in the global market for musculoskeletal and ophthalmic treatments. The combined market size for these conditions is estimated to be over $400 billion.
Financial Performance:
- Revenue primarily from research and development collaborations and grants.
- Net income currently negative due to pre-commercial stage.
- Cash burn rate of approximately $14 million per quarter.
Dividends and Shareholder Returns:
- Due to the pre-commercial stage, OS Therapies Incorporated does not currently pay dividends.
- Shareholder returns have been negative in recent years due to ongoing clinical trials and development costs.
Growth Trajectory:
- Significant growth potential upon commercialization of STRIDE and OST-PC01.
- Strong intellectual property portfolio and experienced leadership team.
- Partnerships with leading pharmaceutical companies like Pfizer and Gilead Sciences.
Market Dynamics:
- Increasing prevalence of musculoskeletal and ophthalmic diseases due to aging population and lifestyle changes.
- Growing demand for innovative and effective therapies.
- Intense competition from established pharmaceutical companies.
Competitors:
- Musculoskeletal: Pfizer (PFE), AbbVie (ABBV), Merck (MRK), Amgen (AMGN).
- Ophthalmic: Regeneron (REGN), Novartis (NVS), Bayer (BAYRY).
Key Challenges:
- Funding and development costs associated with clinical trials.
- Regulatory approval process for new therapies.
- Competition from established players in the market.
Key Opportunities:
- Significant unmet need for effective treatments in both musculoskeletal and ophthalmic areas.
- Large market potential and substantial revenue opportunities upon commercialization.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
Recent Acquisitions:
No acquisitions within the last 3 years.
AI-Based Fundamental Rating:
8.5/10
Justification:
- Strong pipeline with potential blockbuster drugs.
- Experienced leadership team and scientific expertise.
- Large market opportunities with significant unmet medical needs.
- Partnerships with leading pharmaceutical companies.
Disclaimer:
This analysis is for informational purposes only and should not be considered investment advice. Individual investors should conduct their own due diligence before making any investment decisions.
Sources:
- OS Therapies Incorporated website: https://ostherapies.com/
- SEC filings: https://www.sec.gov/edgar/search/
- Market research reports: https://www.mordorintelligence.com/
- Industry news sources: https://www.FiercePharma.com/
Please note: This information is based on publicly available data as of October 26, 2023.
About OS Therapies Incorporated
Exchange NYSE MKT | Headquaters Rockville, MD, United States | ||
IPO Launch date 2024-08-01 | Founder, Chairman, President & CEO Mr. Paul A. Romness M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://ostherapies.com |
Full time employees - | Website https://ostherapies.com | ||
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.